BPC-157 is one of the most discussed peptides in performance and recovery circles — and for good reason. Here's everything sourced from expert transcripts and clinical literature, not broscience.
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protective protein found in human gastric juice. It was first identified by researchers studying gastric ulcer healing and cytoprotection in the 1990s.
Unlike many peptides that target a single pathway, BPC-157 appears to work through multiple mechanisms simultaneously, which is why it shows up in research contexts ranging from tendon repair to gut health to neurological protection.
Full name: Body Protection Compound 157 · Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val · Origin: Derived from human gastric juice protein · Status: Research compound — not FDA approved
BPC-157 exerts its effects through several pathways that have been identified in animal studies and in vitro research:
It's critical to understand the evidence base here. The overwhelming majority of BPC-157 research is in rodent models. There are no completed randomized controlled trials in humans as of 2026. This doesn't invalidate the compound — it means you're extrapolating from animal data and anecdotal reports.
Key findings from animal research include: significantly accelerated Achilles tendon healing, reduced recovery time from muscle tears, protective effects on gut mucosa, and neurological protection in traumatic brain injury models.
Dosing is based entirely on anecdotal use and extrapolation from rodent studies. Vigorous Steve's extensive Q&A library provides the most detailed real-world dosing guidance available:
| Purpose | Dose | Frequency | Duration |
|---|---|---|---|
| Injury recovery | 250–500 mcg | Daily | 4–8 weeks |
| Gut health | 250 mcg | Daily or twice daily | 4–6 weeks |
| Maintenance / prevention | 200–250 mcg | 3–4x/week | Ongoing |
| Conservative start | 100–150 mcg | Daily | 1–2 weeks, then reassess |
The debate between systemic dosing (anywhere on the body) vs. perilesional dosing (near the injury) is ongoing:
For most users: start with subcutaneous injection in the abdomen, fasted in the morning. Move to perilesional if you're treating a specific joint or tendon injury and are comfortable with the technique.
The BPC-157 + TB-500 stack is the most commonly discussed combination in performance recovery circles. Both peptides promote healing but through different mechanisms:
A typical combined protocol for a significant injury (e.g., rotator cuff tear, MCL sprain):
"The combination covers both the local healing cascade and systemic tissue remodeling. I've seen the best results in clients with tendon injuries running both for 8 weeks." — Vigorous Steve
In animal models, BPC-157 has an exceptional safety profile — no lethal dose has been established in rodents even at extremely high doses. In human anecdotal reports, the most commonly reported effects are mild and transient:
There are no documented serious adverse events in the anecdotal literature at typical doses. However, the lack of human trials means unknown long-term risks cannot be ruled out.
For specific questions about your situation — injury type, dose adjustments, stacking considerations, bloodwork — ask Dr Peptidito directly. The knowledge base includes Vigorous Steve's full Q&A library indexed and searchable.
Ask Dr Peptidito — get a cited answer from the knowledge base in seconds.
Ask about BPC-157